Vitrolife Valuation Multiples

Vitrolife Overview

About Vitrolife

Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient’s fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.

Founded

1994

HQ

Employees

1.1K

Website

vitrolife.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $386M

EBITDA: $113M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Vitrolife Financials

Vitrolife reported last 12-month revenue of $386M and EBITDA of $113M.

In the same LTM period, Vitrolife generated $225M in gross profit, $113M in EBITDA, and had net loss of ($380M).

Vitrolife P&L

In the most recent fiscal year, Vitrolife reported revenue of $387M and EBITDA of $111M.

Vitrolife expects next 12-month revenue of XXX and NTM EBITDA of XXX

Vitrolife Stock Performance

Vitrolife has current market cap of $2B, and enterprise value of $2B.

Vitrolife's stock price is $11.80.

Vitrolife Valuation Multiples

Vitrolife trades at 4.4x EV/Revenue multiple, and 14.9x EV/EBITDA.

Vitrolife Financial Valuation Multiples

As of April 20, 2026, Vitrolife has market cap of $2B and EV of $2B.

Equity research analysts estimate Vitrolife's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vitrolife has a P/E ratio of (4.2x).

Vitrolife Margins & Growth Rates

Vitrolife's revenue in the last 12 month grew by 2%.

Vitrolife's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Vitrolife's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vitrolife's rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Vitrolife Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Vitrolife M&A Activity

Vitrolife acquired XXX companies to date.

Last acquisition by Vitrolife was on XXXXXXXX, XXXXX. Vitrolife acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Vitrolife Investment Activity

Vitrolife invested in XXX companies to date.

Vitrolife made its latest investment on XXXXXXXX, XXXXX. Vitrolife invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).